Battling Lung Cancer With Combination Drug TherapyCombination drug therapy may be needed to combat non-small cell lung cancer (NSCLC), according to a study by the Translational Genomics Research Institute (TGen) and Van Andel Research Institute (VARI). The study, "STAT3 is Activated by JAK2 Independent of Key Oncogenic Driver Mutation in Non-Small Cell Lung Carcinoma," was published online by the Public Library of Science (PLoS) ONE...
A New Genetic Subtype Of Lung Cancer DefinedA report from investigators at the Massachusetts General Hospital (MGH) Cancer Center has defined the role of a recently identified gene abnormality in a deadly form of lung cancer. Tumors driven by rearrangements in the ROS1 gene represent 1 to 2 percent of non-small-cell lung cancers (NSCLC), the leading cause of cancer death in the U.S...
News From The Journal Of Clinical Investigation: Feb. 1, 2012 ONCOLOGY: Answers to age-old questions surrounding fat cell cancer Myxoid round cell liposarcoma (MRCLS) is a cancerous tumor that typically arises in deep fat tissues of the limbs or abdomen. It was shown almost 20 years ago to be characterized by a chromosomal change that generates a fusion protein known as TLS:CHOP...
Immunological Mechanisms Of Oncolytic Adenoviral TherapyCancer is one of the most common causes of death in humans. The conventional cancer therapies include surgery, radiotherapy, chemotherapy, and targeting therapies, which are intended to directly destroy and eliminate tumor cells. These treatments often fail, resulting in tumor metastasis and recurrence. Therefore, there is a critical need for novel cancer therapies...
Lung Tumor Gene Test Predicts Surgery OutcomesAn assay which measures the activity of 14 genes in lung cancer tumors can accurately predict who will respond well to surgery and who will probably die within five years, researchers from the University of California, San Francisco, reported in The Lancet...
Smokers Continue Habit After Being Diagnosed With Cancer According to a study published January 23 online in Cancer, many smokers do not drop the habit after being diagnosed with colorectal or lung cancer. The study by Elyse R. Ph.D., M.P.H.and her team at Massachusetts General Hospital, Boston involved 3,063 patients with colorectal cancer and 2,456 with lung cancer. The patients were seen at the time of diagnosis, and also five months later...
After A Cancer Diagnosis, Many People Continue To SmokeA new analysis has found that a substantial number of lung and colorectal cancer patients continue to smoke after being diagnosed. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study provides valuable information on which cancer patients might need help to quit smoking...
Mechanism Of Lung-Cancer Drug Resistance Revealed By StudyNew research published in Nature Medicine indicates that targeted drugs such as gefitinib might more effectively treat non-small cell lung cancer if they could be combined with agents that block certain microRNAs. The study was led by investigators with the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J...
Study Examines Drug Resistance In ALK Positive Lung CancerScientists from the University of Colorado Cancer Center have once again advanced the treatment of a specific kind of lung cancer. The team has documented how anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) becomes resistant to a drug targeting the abnormal protein in the cancer...
TB And A Gene Mutation That Causes Lung Cancer LinkedTuberculosis (TB) has been suspected to increase a person's risk of lung cancer because the pulmonary inflammation and fibrosis can induce genetic damage. However, direct evidence of specific genetic changes and the disease have not been extensively reported...
Early-Stage Non-Small Cell Lung Cancer - Malignancy Gene Signature FoundAccording to an investigation published in the recent issue of the Journal of the National Cancer Institute, researchers at Moffitt Cancer Center in Tampa, Florida have discovered that a malignancy-risk gene signature created for breast cancer has predictive and prognostic value for individuals suffering with early stage non-small cell lung cancer (NSCLC)...
As Monotherapy And In Combinations, Ganetespib Showed Activity In KRAS-Mutant NSCLCThe investigational drug ganetespib, a synthetic second-generation Hsp90 inhibitor, slowed the growth of cancer cells taken from non-small cell lung cancer tumors with a mutation in the KRAS gene. The drug was even more active when combined with traditional lung cancer treatments and other investigational targeted therapies, according to preclinical study data. David A. Proia, Ph.D...
Circulating Tumor Cells Analyzed In Patients With Lung CancerResearchers have developed a method to analyze circulating tumor cells in the blood of patients with non-small cell lung cancer. This method, which can analyze a sample size as small as three cells, may allow clinicians to track cancer progress and treatments and could help them develop new therapies...